Ironwood Pharmaceuticals Inc - Class A

Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company focused on developing and commercializing therapies for gastrointestinal (GI) and rare diseases. Its primary commercial product is LINZESS (linaclotide), the #1 prescribed brand in the U.S. for the treatment of irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) in adults, and functional constipation (FC) in pediatric patients 2 years and older. LINZESS is co-developed and co-commercialized with AbbVie in the U.S., with profits shared equally under a collaboration agreement. International partners include Astellas (Japan), Grand Life Sciences (China), and AbbVie (all other territories). The company is also advancing apraglutide, a next-generation, once-weekly, long-acting synthetic GLP-2 analog in Phase 3 development for short bowel syndrome with intestinal failure (SBS-IF), a rare and severe malabsorptive condition. Ironwood's revenue is predominantly derived from its share of LINZESS U.S. collaboration profits, supplemented by royalty income from international sales. The company has a negative stockholders' equity position reflecting its accumulated deficit, and carries debt on a revolving credit facility. Updated Aug 6, 2026